Notification of a concentration concerning the acquisition by Recordati S.p.A., of assets which belong to Novartis group of companies, via A.G. Recordati
The Service of the Commission for the Protection of Competition announces that it has received a notification of a concentration from
concerning the acquisition
of assets which belong to Novartis group of companies, via A.G. Recordati
Recordati S.p.A. is a company duly registered under the laws of Italy. Recordati A.G. is a company duly registered under the laws of Switzerland which belongs to Recordati S.p.A.. Recordati group is a pharmaceutical group that engages in research, development, manufacture and marketing of medicines for primary care and pharmaceutical products that have not been commercially developed (ophan drugs) for treating rare diseases.
The target in this concentration is the assets of the Novartis group which relate exclusively to the two pharmaceutical products Signifor LIAM and Signifor LAR as well as to the chemical compound that is in the process of development concerning adult treatment for Cushing disease.
Copyright © Republic of Cyprus 2020,
Commission for the protection of Competition
Designed and Developed by the Department of IT Services